



Artificial Intelligence for Drug Discovery


Q1 2025



www.deep-pharma.tech



AI in Drug Discovery
Industry
Q1 2025




Companies – 3800
Investors – 4900
Clinical trials – 5000
Personalities – 750
Hubs – 600



View more:
www.deep-pharma.tech

Pharma Efficiency: Challenges



10 years + \$2.6 bln = 1 new drug


It takes on average over 10 years to bring a new drug to market. As of 2014, according to Tufts Center for the Study of Drug Development (CSDD), the cost of developing a new prescription drug that gains market approval is approximately \$2.6 billion. This is a 145% increase, correcting for inflation, compared to the same report made in 2003.

The pharmaceutical industry is in a terminal decline, and the returns on new drugs that do get to market do not justify the massive investments that Pharma currently puts into R&D anymore.

The solution to this problem comes from three key strategies:


- evolution of business models towards more collaboration and pipeline diversification early
- **implementation of AI as a universal shift towards data-centric drug discovery**
- discovery of new therapeutic modalities (biologics, therapies, etc.)

Pharma's "AlphaGo Moment"




Computer-Aided Drug Design


Today's task for the pharma industry is to create a cheap and effective solution for drug development, companies apply various computational methods to reach that goal. **Computer-aided drug design (CADD)** is a modern computational technique used in the drug discovery process to identify and develop a potential lead. CADD includes computational chemistry, molecular modeling, molecular design and rational drug design.
















Application of AI for Advanced R&D to Address Pharma Efficiency Challenges



Comparison of Top-50 Leading AI for Drug Discovery Companies Expertise in Drug Discovery R&D




Selected Pharma AI Deals

AI Companies	Pharma Corporations	AI Companies
            		           
         		       
       		       
      		      
         		           
       		       

Note: the central column (red) defines the pharmaceutical corporations and side columns (blue) defines AI companies that have collaborations with pharma companies from the central column.

10 Most Recent Acquisitions of AI in Drug Discovery Companies

March 2025  LexisNexis®
RISK SOLUTIONS



HUMAN API


 InstaDeep™

\$440M

BIONTECH

January 2025

February 2025




OKRA




\$29M

CERTARA

January 2025

February 2025



 trials.ai

nimbus
THERAPEUTICS

\$4B



December 2024

January 2025

Paradigm

\$200M



 **AMPLION**

undisclosed



September 2024

January 2025

CAMBRIDGE
COGNITION

\$7M




 **PeerWell**

undisclosed




June 2024

3900 AI Companies: Regional Proportion



The US is still firmly in the lead regarding its proportion of AI for Drug Discovery companies. Interestingly, Asia and the Middle East continue to expand usage of AI technologies in the Pharmaceutical Industry. The ratio of companies that use AI for Drug Development in the UK and European countries is decreasing compared to the Asian market. The Asia-Pacific region continues to aggressively increase the number of AI for Drug Discovery Companies, particularly in China, and this tendency will probably maintain.

AI in the Global Context



Europe Actively Explores AI Applications for Drug Discovery

In Europe, the European Medicines Agency (EMA) has announced plans to use AI to improve the efficiency of its work, including the assessment of new drug applications. The UK's National Health Service (NHS) is also exploring the use of AI to improve patient care, including the development of personalized medicine.

US is a Main Player in AI Industry

In the beginning of AI implementation, US was a pioneer and then the main player with the greatest number of companies using AI to force R&D, research centres and institutes, and investments. The US Food and Drug Administration (FDA) has also established a program to explore the use of AI in regulatory science.

Asia Invest in AI in Drug Development Activity

In Asia, Japan and South Korea are also investing in AI for drug development. Japan's Ministry of Economy, Trade, and Industry has established a program to promote the development of AI-based drug discovery technologies, and South Korea is investing in AI research and development through its national program, "AI Korea."

China Plans to Become the World AI Leader by 2025


The National Development and Reform Commission, China's top economic planning body, has identified AI in the pharmaceutical industry as a key area for development under its "Made in China 2025" plan. This plan aims to make China a global leader in advanced manufacturing, including the development of AI-based technologies.

Top-10 AI-Driven Publicly Traded Companies by Market Capitalization in 2025




The chart represents the top-10 public companies that ended up in Deep Pharma Intelligence portfolios according to their market capitalization in 2025. The Top-3 companies by Market Capitalization in 2025 are **Eli Lilly and Company (\$2.8B)**, **Johnson & Johnson (\$2.7B)** and **Merck & Co., Inc. (\$2.3B)**. All of them belong to different areas of Drug Development, such as **End-to-End Drug Development**, **Early Drug Development** and **Clinical Development**, highlighting that **utilization of AI increase gradually in most of the areas of Drug Discovery**.

Leading Companies by Amount and Stage of Funding Raised by 2025




Top 10 Funded Companies in Q4 2024 vs Q1 2025

Top 10 Funded Companies in Q4 2024



Top 10 Funded Companies in Q1 2025




To visualise yearly trends, the charts represent the **top 10 funded companies in Q4 2024 and Q1 2025**. The observed central tendency is the decrease in investments in Q1 2025 compared to Q4 2024. The most significant raised investment in **Q1 2025** was in **Verily** company, which raised **\$3.5B**, while in **Q4 2024**, **Neumora** raised **\$320M**. The **average investment in Q4 2024** was **\$49.7M**, while in **Q1 2025**, it was **\$37.7M**. Additionally, the number of assets is almost two times smaller in 2024 (**27 investments in Q1 2025 to 49 investments in Q4 2024**).

Big Pharmas' AI-focused partnerships till Q4 2024

In this report we have profiled **800 actively developing AI-driven biotech companies**. A steady growth in the AI for Drug Discovery sector can be observed in terms of substantially increased amount of investment capital pouring into the AI-driven biotech companies (**\$48.19B in HY 2024** against **\$126.4B in HY 2024**), the increasing number of **research partnerships between leading pharma organizations and AI-biotechs, and AI-technology vendors**, a continuing pipeline of industry developments, research breakthroughs, and proof of concept studies, as well as exploding attention of leading media and consulting companies to the topic of AI in Pharma and healthcare.


Some of the leading pharma executives increasingly see AI as not only a tool for lead identification, but also a more general tool to boost biology research and identify new biological targets and develop novel disease models.

The main focus of AI research for today is still on small molecules as a therapeutic modality.



A Growing Number of Collaborations Involving AI for Drug Discovery

Increasing number of partnerships between Big Pharma and AI Companies over the last 6 years



The rising interest of the big pharma companies towards AI-driven biotech startups is a major driver for the area to become more attractive for investors, since the industry is becoming well-suited for successful exit strategies in future.

Summarizing industry observations over the last five years, we can observe a fundamental shift in perception of top executives at leading pharmaceutical organizations about the need of advanced AI technologies. Since 2017, there has been an obvious shift in the perception from skepticism and cautious interest, all the way to a realization of a strategic role AI has to play in the emerging “data-centric” model of innovation. This change in perception was underpinned by a number of factors:

- a wave of proof-of-concept studies and research breakthroughs in a wide range of AI application use cases
- a number of commercial successes and successfully reached milestones, involving AI as a central element of research
- substantial advances in democratizing AI technology, where machine learning and deep learning algorithms become available at scale to non-AI experts
- decent increase in the overall understanding of AI “mechanics”, due to increasing efforts in the education and professional development with a focus on AI-driven tools and approaches

Pharmaceutical companies of all sizes start competing for AI-expertise, talent, and partnerships. In this report we summarize some of the most high-profile such collaborations, involving top-20 pharma giants. Even though, we can see a clear uprising trend in the number of collaborations, focused on AI-drug design, and other aspects of data mining and analytics.

Corporation and AI-companies Participating in the Pharma AI Deals

Pharma Partners



AI and Biotech Partners



Tech partners



Notable AI Breakthroughs

Oct 2024

Two additional novel **AI-generated targets** for chronic kidney disease and idiopathic pulmonary fibrosis discovered using the **Benevolent Platform™** selected to enter **AstraZeneca's** drug discovery portfolio.

Nov 2024

Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data through the **MELLODDY** platform, but not directly with each other or with Owkin. Substra is the software that made this possible. Instead, an **AI studied each dataset** the business had in turn to learn, retaining no actual data but a great deal of aggregate impressions.

Nov 2024

PatSnap, a global leader in innovation intelligence, launched **Eureka today**, an artificial intelligence (AI) powered solution that makes intellectual property (**IP**) **more accessible for Research and Development (R&D) engineers**. Eureka optimizes searches, technical insights, competitor monitoring, and collaboration for organizations.

Dec 2024

MindRank Announces U.S. FDA Clearance of IND Application for **MDR-001**, a Novel GLP-1 Receptor Agonist for the Treatment of **Type 2 Diabetes and Obesity**.

Dec 2024

Owkin is open sourcing **Substra**, its **Federated Learning (FL) software**, to allow researchers and developers to collaboratively train ML models without the data leaving its source.

Notable AI Breakthroughs

Jan 2025

Evozyne revealed AI model, developed in collaboration with **NVIDIA**, that the pharmaceutical industry can use to design therapeutic proteins. The model, called the **Protein Transformer Variational AutoEncoder (ProT-VAE)**.

Jan 2025

BigHat Biosciences, Inc., announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with **Amgen** applying BigHat's platform for multi-objective optimization of a next-generation antibody.

Feb 2025

BenchSci has launched **a new AI software** that aims to expedite preclinical phase drug development pipelines by extracting biological insights underlying disease. The **end-to-end SaaS** (software as a service) platform, **ASCEND**, enables the discovery of biological connections, reduces unnecessary experiments, and uncovers risks at early stages.


Feb 2025

Insilico Medicine Announces IND Approval of Oral 3CLpro Inhibitor **ISM3312** for COVID-19.


Mar 2025

Mitsui & Co., Ltd. is collaborating with **NVIDIA** on **Tokyo-1** – an initiative to supercharge the nation's pharmaceutical leaders with technology, including high-resolution molecular dynamics simulations and generative **AI models for drug discovery**.

Drug Candidates Designed by AI: Global




Computational Methods Used by the Most Advanced AI Companies



Introduction to Most Innovative R&D Approaches of AI in Biopharma

Biopharma utilizes living organisms (such as yeasts, bacteria, and mammalian cells) which are capable to produce complexly structured products such as proteins, hormones, RNA and DNA products, and virus capsids. Whereas Pharma relies on a classical chemical synthesis producing small drug molecules. However, both industries may benefit from AI-driven applications. To develop new small drug molecules or biologically-derived products, AI-driven data processing serves as a tool that allows minimising time consuming biological testings while helping to select the most promising products to test.



What Datafoundry Solutions Can Do for Your R&D

DF Digitalize AI



Integrators/Connectors to ingest data from various enterprise systems

Managed professional services for end-to-end implementation



Extract data from unstructured documents and flat files using 99.5 % accurate OCR and NER models.

A team of experts drawn from Datafoundry and our partner ecosystem



Provide the data as a curated, structured repository for insights and analytics

Built upon a compliant framework to assure data integrity & privacy

Intelligent Solution that ingests and digitizes data from multiple sources, to create a curated and structured data warehouse for deployment of composable applications and analytics, for **business critical decisions**.

DF mSafety AI

DF mSafety AI is the solution to **address your key challenges in Safety Management** – from case intake and triage through medical review and regulatory submission.



Automate Case Intake & Triage



Auto Narrative Generation



Signal & Risk Management



Seriousness Prediction



Case Compliance Alerts



Literature Monitor for Safety



Casualty Assessment

DF mSignal AI

DF mSignal AI is a **modular, scalable** and **secure signal management system** that can be integrated with leading safety databases.



Integration with the most Regulatory Databases



Real-time Monitoring of Drug-Event combinations



In-built QC Feature to approve/reject a signal report



Uses Advanced Data Mining Algorithms



Networks for Higher Accuracy in Signal Detection



Configurable Alert Thresholds



Store Statistical Results and Track Signal Review



Subset Statistical Results



Insightful Graphical Presentation and Analytics

Most Innovative R&D Approaches of AI in Biopharma. Antiverse

Antiverse is a new type of antibody discovery company accelerating drug development. The Antiverse platform exists at the intersection of structural biology, machine learning and medicine to enable breakthroughs to happen more quickly and cost-effectively.

Antiverse **prevents diversity loss** during amplification to uncover more diverse and rare antibodies.

Traditional in vitro screening:

10^{10} antibodies



3 amplification rounds



10 antibodies

Antiverse discovery:


Antigen-antibody database



AI-augmented screening



96 antibodies



Antiverse **provides more candidates** by analysing NGS data, clustering on multi-dimensional space, and selecting based on sequential and structural grouping. The generative module **offers new sequences** and gives you options that haven't even been considered.

Antiverse AI-Augmented Discovery:

Antigen-antibody database

Recovery Module

Generative Module

96 antibodies

How Do Robotics and AI/ ML Synergize in Drug Discovery?

The greatest challenge in AI-driven and ML-powered drug discovery is access to well structured, fully annotated, reproducible and robust data. **Arctoris** leverages the power of robotics to generate vast amounts of **ML-ready data that enable better decisions** - thereby significantly accelerating timelines from target to hit, lead, and candidate.

INDUSTRY-STANDARD DATA GENERATION & PROCESSING



- Widespread lack of reproducibility
- Unclear reagent and cell line provenance
- Inconsistent use of methods & protocols
- Human error & variability
- Only collection of high-level results data
- Highly fragmented file & storage systems

ARCTORIS-ENABLED DATA GENERATION & PROCESSING

- Strict adherence to automated protocols
- Fully verified reagents and cell lines with complete audit trails
- Reproducible results data in standardized structure
- Additional collection of rich research meta-data
- Secure & convenient data storage & access
- Advanced assay performance monitoring

Both quality and speed are achieved by combining precision robotics with a unique data science platform and world-class drug discovery expertise from biotech and pharma veterans.

Arctoris tracks all experimental outputs in full depth, including the capture and analysis of extensive metadata – temperature, humidity, CO₂, reagent provenance and batch ID among many others. At the same time, the platform enables automated QA/ QC processing, applying statistical tools to ensure full reliability and validity of all results.

Thereby, **Arctoris** ensures **superior data to be generated in accelerated timeframes**, leading to better decisions taken earlier - in human-powered but especially in AI/ ML-driven programs, thanks to training of AI models with the best possible data.

Taken together, **Arctoris** has developed a **unique technology platform** based on robotics and data science that powers drug discovery programs both in the company's internal pipeline and in partnerships with biotech and pharma companies worldwide.

How GATC Health Uses AI in R&D

Diagnostic Biomarker Discovery

- Diagnostic biomarkers are discovered on a dataset.
- Biomarkers are mathematically assessed for causal and effect impacts.
- Validated causal biomarkers and pathways are simulated and evaluated by AI-assisted database models and human expertise.
- A final set of treatment targets emerges.

Drug Compound Discovery

- Identifies the causal relationship between the biomarkers and the disease to illuminate insights into the disease.
- AI-assisted compound discovery is used to produce a set of novel treatment compounds.
- The targets and compounds are prioritized and documented for pre-clinical testing.

Pre-Clinical De-Risking of Drug

- Develop new therapeutics using in-silico and in-vivo clinical studies with more comprehensive analysis.
- Ensure higher levels of success as the drug progresses through FDA trials.
- Eliminate majority of the risk and cost associated with treating the disease.

GATC Health Time to Drug Discovery

6-9
months

Source &
Identity
Patient Data

Rapid therapeutic
targeting



Automated
disease modeling



De-Novo therapeutic
assembly



Molecular
synthesis

Pre-clinical
Trials




How Standigm Accelerates Drug Discovery using AI



Standigm®

Standigm is a workflow AI-driven drug discovery company headquartered in Seoul, South Korea and subsidiarized in Cambridge, UK. Standigm has proprietary AI platforms encompassing novel **target identification to compound design**, to generate commercially valuable drug pipelines. The company has established an early-stage drug discovery workflow AI to generate First-in-Class lead compounds within seven months. o date, Standigm is running 42 in-house or collaborative pipelines for drug discovery using the workflow AI technology. One of the company's pipelines is expected to enter a pre-clinical stage in 4Q 2021.

Standigm BEST™ is a novel **compound generation platform**, which can investigate lead compounds whenever target or ligand information is lacking or enough.


Standigm ASK™ is a customizable, AI-aided **drug target identification platform**, prioritizing disease-target relationships and providing evidence-based results through an interactive user interface.

Database	Hit ID	Hit to Lead	Lead Optimization
 Deep learning chemical space 150-dimensional vector space which learned various compound properties	 Securing activity Accurate prediction of binding	 Securing novelty New scaffold with various structures	 Druggability optimization Mainly-based substructural variation 3D-based druggability prediction

Graph DB	Prioritization Algorithm	Multi Filters	Novel Target Selection
 Biomap (Knowledge + Omics)	 Target prioritization based on disease-target-association scores	 Screening attractive target's with multi filters	 Novel Target Selection

How Standigm Accelerates Drug Discovery using AI


Standigm Releases First-in-Class Compounds within 7 Months




Featured Partners



Standigm made the hit-to-lead stage with a cancer Target A within 7 Months



Collaborator (Pharma Company): 3M (Hit Compounds)




*Data Analysis – Binding site analysis using protein structure


**Model Validation – Validation of activity prediction models: ChemMap-based, 2D structure QSAR-based, Simulation-based and Ensemble-based methods

Most Innovative R&D Approaches of AI in Biopharma. Strados Labs

Strados Labs enters the Pharma and Life Science market with a **Respiratory Management Solution** that includes the only FDA-cleared, RESP biosensor which acquires lung sound acoustics wireless and hands-free, making it a perfect fit for clinical research to measure patient response to new drugs by objectively collecting coughs and other lung sounds discreetly, comfortably, and securely in a streamlined way, while having access to data for post-processing and analysis.



How Strados Labs Uses AI in R&D?



Strados Labs — a respiratory management solution, which brings innovation at the intersection of lung biomarkers, patient centricity, and machine learning. The industry of life sciences can largely benefit from the enhancement of pulmonary care monitoring capabilities provided by Strados Labs to gain insight into patient drug response by analysis of longitudinal lung acoustics.

220 hours of continuous data collection without patient intervention of objective lung sounds and respiratory dynamics while having access to data for post-processing and analysis.

Noise cancellation is applied to enhance the signal to noise ratio and eliminate speech discernibility while being HIPAA compliant with an end to end encryption.

Data collected via RESP is uploaded automatically to the Strados Cloud to allow assessment of recordings timely with identification of adventitious breath sounds including respiratory dynamics with ML algorithms.

Wireless, non invasive biosensor that monitors, records and stores every lung sound. That translates into longer wear times and an astounding 99.59% patient compliance.

Identification of wheeze, cough, and CABS detection gives the objective measurement of these changes over time on a patient and population basis with an ability to differentiate cough types in addition to frequency.

**Data Collection
Capacity**

**Patient Privacy
& Security**

**Real-Time Data
Analysis**

**Patient
Centricity**

**Longitudinal
Lung Data**

Biggest Deals 2024-2025


The total amount of VC funding in AI in drug development companies reached to \$60.2B in Q1 2025.

There is an increasing number of late-stage mega-rounds including hundreds of millions. The apparent trend is sector consolidation, where a number of AI-startups have achieved substantial leadership and grown in resources and technology. An important driver of growth for the sector is a substantial shift in Big Pharma's interest in AI technology, making AI an important integral part in the research and implementation areas.

Top 5 highest fundings received the following companies:

1. **Verily** with \$1000 million (Corporate Round)
2. **Relay Therapeutics** with \$300 million (Post-IPO Equity)
3. **Biofourmis** \$300 million (Series D)
4. **Freenome** with \$290 million (Corporate Round)
5. **Treeline Biosciences** with \$260million (Series A)

Biggest Funding 2023-2025



Deep Pharma Intelligence – New Era in Pharma Analytics

Deep Pharma Intelligence (DPI), an analytical subsidiary of Deep Knowledge Group, is a highly specialised think tank in the area of BioTech innovation profiling, market intelligence, and BioTech development advisory. The company is dedicated to producing powerful data mining and visualisation systems, interactive analytics tools, and industry reports, offering deep technical insights, market intelligence, and strategic guidance in the high growth and significant opportunity areas.

DPI is Focusing on Three Key Activities:


Conducting Market Intelligence

Producing regular **open-access** and **proprietary reports** on the emerging topics and trends in the pharmaceutical and healthcare industries. All reports are supported by our back-end analytics systems and tools that allow to receive fresh insights and updates about opportunities and risks.



Creating Big Data Analytical Dashboards

Building a comprehensive **Big Data Analytical Dashboard** (SaaS) as a one-stop-platform for all market and business intelligence operations our customers may need, including profiling thousands of companies, market signals and trends based on tens of millions of constantly updated data points.



Producing Scientific Content

DPI provides a **full-cycle development of articles, scientific journals, and books**. We are ready to develop a detailed Requirement Specifications document, including layout of the journal, fully designed brand book, with example templates for each chapter.



AI in Drug Discovery Analytical Dashboard

AI in Drug Discovery Analytical Dashboard is a fundamental tool for strategic insights, opportunity evaluation, competitor profiling, and other purposes relevant to Pharma and BioTech decision-makers, life science investors, consulting companies, and regulatory agencies.

600	Companies
1,100	Investors
290	R&D Collaborations
120	Clinical Trials
170	Parameters of Automated SWOT Analysis



Market Intelligence Focus

Automated SWOT Analysis	Stock Price Forecasting	Interactive Chart Builder
Automated Competitive Analysis	Financial Portfolio Constructor	Matching Tool for Investors

Forms of Proposed Cooperation

Deep Knowledge Group offers a variety of collaboration and cooperation options for parties seeking to enhance their strategic decision making, corporate and operational intelligence, and tactical execution capabilities by accessing one or more of our 70+ health and life sciences-focused Big Data Analytical Dashboards and Market Intelligence Systems.

We offer access to our Dashboards across 3 tiers: Subscription (baseline access to tools and components), White Label Solution (access to full scope of features with certain degrees of customization, personalization and plug-and-play feature selection), and Custom Dashboard Creation (end-to-end customized solution tailored to your specific operational needs and requirements).

Big Data Analytics Dashboard Subscription

- Subscription access is the most economical option for parties seeking to utilize our dashboards
- Offers full scope of ready-for-use analytics, corporate and competitive intelligence, market monitoring and benchmarking tools
- Discounted rates for multi-dashboard access available.


Big Data Analytics Dashboard White Label Solution

- Enhanced access to a wider scope of Dashboard features and functionality
- Includes a certain degree of client-directed Dashboard component and functionality customization and personalization and plug-and-play feature selection
- Highly flexible choice of data sources

Custom Market Intelligence Dashboard Creation

- End-to-end custom solution tailored to the operational and organizational needs and specifics of the client
- Plug-and-play feature selection
- Ground-up custom design of new components according to client need
- Most versatile, customizable and sophisticated option available

We are open to a mutually beneficial cooperation



Link to the Report: www.deep-pharma.tech/ai-in-dd-q3-2024-subscribe

E-mail: info@deep-pharma.tech

Website: deep-pharma.tech

Deep Pharma Intelligence (DPI) Disclaimer

The information and opinions in this report were prepared by Deep Pharma Intelligence. The information herein is believed by DPI to be reliable but DPI makes no representation as to the accuracy or completeness of such information. There is no guarantee that the views and opinions expressed in this communication will come to pass. DPI may provide, may have provided or may seek to provide advisory services to one or more companies mentioned herein. In addition, employees of DPI may have purchased or may purchase securities in one or more companies mentioned in this report. Opinions, estimates and analyses in this report constitute the current judgment of the author as of the date of this report. They do not necessarily reflect the opinions of DPI and are subject to change without notice. DPI has no obligation to update, modify or amend this report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, estimate, forecast or analysis set forth herein, changes or subsequently becomes inaccurate. This report is provided for informational purposes only. It is not to be construed as an offer to buy or sell or a solicitation of an offer to buy or sell any financial instruments or to participate in any particular trading strategy in any jurisdiction.